Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Sinemet(R) Tablets
Date:11/5/2008

DETROIT, Nov. 5 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE: CPD) announced today, that it has launched Carbidopa and Levodopa tablets on behalf of Sun Pharmaceutical Industries Ltd. (Sun Pharma). Sun Pharma recently received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for generic Sinemet(R) tablets.

Carbidopa and Levodopa tablets are used in the treatment of Parkinson's disease and syndrome. These generic versions of Carbidopa and Levodopa 10 mg / 100 mg, 25 mg / 100 mg, and 25 mg / 250 mg tablets are bioequivalent to Sinemet(R) tablets distributed by Bristol-Myers Squibb. According to IMS Data, these strengths of Carbidopa and Levodopa had US. sales of approximately $70 million for the 12-month period ended June 2008.

Daniel H. Movens, Caraco's Chief Executive Officer, said, "We are pleased to add to our product portfolio by launching Carbidopa and Levodopa tablets immediately to the marketplace. We continue to focus on working towards expanding our product offering as quickly and effectively as possible."

Sinemet(R) is a registered trademark of Merck & Co.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or cheaper products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Reaches Agreement with Labor Union
2. Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Depakote(R) Delayed Release Tablets
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Elavil(R)
4. Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008
5. Caraco Pharmaceutical Laboratories, Ltd. to Announce Fourth Quarter and Fiscal Year 2008 Results on May 29, 2008
6. Caraco Pharmaceutical Laboratories Ltd. Wins Summary Judgment on Generic Ultracet(R)
7. Caraco Pharmaceutical Laboratories Ltd. To Market Generic Ethyol(R)
8. Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R)
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... 2016 , ... If you don’t mind a bit of prickly therapy to ... to consider a treatment that some have called the next great tool in dermatology ... also known as skin needling, is a procedure using a device covered with tiny, ...
(Date:5/5/2016)... ... May 05, 2016 , ... MAP ... Platform, announced today that Enlightened Solutions has joined the Premier Outcomes-Driven Provider Network. ... care continuum for their patients being treated for substance use. , Enlightened Solutions ...
(Date:5/5/2016)... ... May 05, 2016 , ... Nepenthe Laboratory Services (NLS), a ... last week to raise non-perishable food item donations for Food for Lane County, and ... on NBC. , “The goal of the assembly was to create an exciting atmosphere ...
(Date:5/5/2016)... ... 2016 , ... In an effort to increase public awareness ... promotion and research organization, declared May as “National Sunshine Month.” , With ... cultural behavior over the past several decades, Americans spend more time indoors than ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ProList is a ... Pro X . With ProList, editors can easily create lists for presentations, youtube ... create additional bullet points. ProList is the perfect complement to presentation style videos. ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... NEW YORK , May 4, 2016 ... Size, Share, Development, Growth and Demand Forecast to 2022 - ... End User (Hospital, Diagnostic Center and Others)" by P&S Market ... at $4,894.3 million in 2015, and it is expected to ... slice type, the high slice type segment is expected to ...
(Date:5/4/2016)... , May 4, 2016 ... concluded a series of free workshops across ... global requirements for Good Distribution Practices (GDP). ... which ensures that products are consistently stored, transported and ... authorization (MA) or product specification. Only a few years ...
(Date:5/4/2016)... May 4, 2016 ... the  "Global Multiple Myeloma Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... and Competitive Landscape Highlights 2016, provides comprehensive ... Myeloma epidemiology, Multiple Myeloma market valuations and ...
Breaking Medicine Technology: